[1] Rinaldi L, Pafundi PC, Galiero R, et al. Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review. Antioxidants, 2021,10(2):270.
[2] Peng C, Stewart AG, Woodman OL, et al. Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. Front Pharmacol,2020,11:603926.
[3] Marchisello S, Di Pino A, Scicali R, et al. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci,2019,20(8):1948.
[4] Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell,2012,148:852-871.
[5] Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature,2006,444:840-846.
[6] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016,64:73-84.
[7] Younossi ZM, Corey KE, Lim JK. AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology,2021,160:912-918.
[8] Sinaiko AR, Caprio S. Insulin resistance. J Pediatr,2012,161:11-15.
[9] Stefan N, Häring HU. The role of hepatokines in metabolism. Nat Rev Endocrinol, 2013,9:144-52.
[10] Liu PW, Chang TY, Chen JD. Serum uric acid and metabolic syndrome in Taiwanese adults. Metabolism,2010,59:802-807.
[11] Alexopoulos AS, Crowley MJ, Wang Y, et al. Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. Hepatology, 2021,74:1220-1233.
[12] Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med,2008,358:2545-2559.
[13] Nakamura A, Yoneda M, Fujita K, et al. Impact of glucose tolerance on the severity of non-alcoholic steatohepatitis. J Diabetes Investig 2011;2:483-489.
[14] Azzu V, Vacca M, Virtue S, et al. Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease. Gastroenterology, 2020,158:1899-1912.
[15] DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care,2013,36 Suppl 2:S127-138.
[16] Gallwitz B. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents. Drugs,2011,71:1675-1688.
[17] Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med,2021,384:1113-1124.
[18] Muscogiuri G, Cignarelli A, Giorgino F, et al. GLP-1: benefits beyond pancreas. J Endocrinol Invest,2014,37:1143-1153.
[19] Rosenwasser RF, Sultan S, Sutton D, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes,2013,6:453-467.
[20] Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol,2012,8:495-502.
[21] Satirapoj B, Korkiatpitak P, Supasyndh O. Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: a randomized controlled trial. Clin Kidney J,2019,12:326-332. |
